



HAL
open science

Intensive end-of-life care in acute leukemia from a French national hospital database study (2017–2018)

Sébastien Salas, Vanessa Pauly, Margaux Dange, Veronica Orleans, Guillaume Fond, Régis Costello, Laurent Boyer, Karine Baumstarck

► **To cite this version:**

Sébastien Salas, Vanessa Pauly, Margaux Dange, Veronica Orleans, Guillaume Fond, et al.. Intensive end-of-life care in acute leukemia from a French national hospital database study (2017–2018). *BMC Palliative Care*, 2022, 21 (1), pp.45. 10.1186/s12904-022-00937-0 . hal-03925699

HAL Id: hal-03925699

<https://hal.science/hal-03925699>

Submitted on 11 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



Intensive end-of-life care in acute leukemia from a French national hospital database study (2017–2018)

Sébastien Salas¹, Vanessa Pauly², Margaux Damge¹, Veronica Orleans², Guillaume Fond^{2,3}, Régis Costello⁴, Laurent Boyer^{2,3} and Karine Baumstarck^{3,5*}

Abstract

Background: A better understanding of how the care of acute leukemia patients is managed in the last days of life would help clinicians and health policy makers improve the quality of end-of-life care. This study aimed: (i) to describe the intensity of end-of-life care among patients with acute leukemia who died in the hospital (2017–2018) and (ii) to identify the factors associated with the intensity of end-of-life care.

Methods: This was a retrospective cohort study of decedents based on data from the French national hospital database. The population included patients with acute leukemia who died during a hospital stay between 2017 and 2018, in a palliative care situation (code palliative care Z515 and/or being in an inpatient palliative care support bed during the 3 months preceding death). Intensity end-of-life care was assessed using two endpoints: High intensive end-of-life (HI-EOL: intensive care unit admission, emergency department admission, acute care hospitalization, intravenous chemotherapy) care and most invasive end-of-life (MI-EOL: orotracheal intubation, mechanical ventilation, artificial feeding, cardiopulmonary resuscitation, gastrostomy, or hemodialysis) care.

Results: A total of 3658 patients were included. In the last 30 days of life, 63 and 13% of the patients received HI-EOL care and MI-EOL care, respectively. Being younger, having comorbidities, being care managed in a specialized hospital, and a lower time in a palliative care structure were the main factors associated with HI-EOL.

Conclusions: A large majority of French young adults and adults with acute leukemia who died at the hospital experienced high intensity end-of-life care. Identification of factors associated with high-intensity end-of-life care, such as the access to palliative care and specialized cancer center care management, may help to improve end-of-life care quality.

Keywords: Acute leukemia, End-of-life care, Palliative care, Registry database, Health services research

Background

Despite the progress made in recent decades, cancer, including hematological malignancies, remains the leading cause of premature death in adults in France

(Institut National du Cancer). Acute leukemia, a heterogeneous group of hematological malignancies characterized by the clonal and malignant proliferation of blasts, is responsible for bone marrow failure. Acute myeloid leukemia is generally diagnosed in patients over 60 years of age (median age 70 years), and its incidence increases with age [1]. Acute lymphoid leukemia is the most common cancer in children and accounts for only 20% of leukemia in adults [2]. Due to the nature of the disease

*Correspondence: karine.baumstarck@univ-amu.fr

⁵ Department of Epidemiology and Health Economics, APHM, Marseille, France

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

and the complications associated with intensive/aggressive treatments, such as allogeneic haematopoietic stem cell transplantation, patients with acute leukemia endure physical and psychological suffering throughout their treatment and their end-of-life care [3–6]. Although new therapies have emerged in recent years that have prolonged survival, many patients experience relapsed disease and die from their malignancy [1, 7, 8].

Since the 2000s, the quality of end-of-life care was improved with the integration of palliative care (<https://www.who.int/cancer/palliative/definition/en/>), characterized by a multidisciplinary approach in the management of patients with advanced or progressive chronic disease [6, 9]. However, at the end of life, compared with patients with solid tumors, previous studies showed that patients with hematological malignancies are less likely to access palliative care [4, 10–12], are less likely to enroll in a homecare process or rehabilitation center [13, 14], and receive more intensive and aggressive care treatment ([13, 15–17], Johnston, [18] #32, [19, 20]). Several possible explanations for this finding have been suggested: disease-related complications similar to treatment-related complications, sudden and uncertain transitions to a palliative approach to care, strong bonds between staff and patients, hematologic oncologists who are less comfortable discussing death and dying, and unrealistic clinician and/or patient expectations [11, 15, 17].

Among the previous studies, some report data older than 10 years [4, 11–13, 16], from a single center [4, 12, 16], from heterogeneous individuals [19], or focused on old [21] or young populations [18, 20]. Few of them specifically explored patient- and hospital-related factors associated with intensive care treatments at the end of life. In France, a better understanding of how the care of acute leukemia is managed in the last days of life would help clinicians and health policy makers improve the quality care during this special period, while taking into account the wishes of the patients and their families.

This study provides robust and recent information from the French national hospital database about the intensity of care near the end of life for patients with acute leukemia. The objectives of this study were: (i) to describe the intensity of end-of-life care among adult patients (and adolescents) with acute leukemia who died in the hospital from 2017 to 2018; and (ii) to identify the factors associated with the intensity of end-of-life care.

Methods

Data source

This was a French population-level retrospective cohort study based on data extracted from the French national hospital database (Programme de Médicalisation des Systèmes d'Information, PMSI). The PMSI is an exhaustive

public and private hospital database inspired from the US Medicare system. The PMSI is based on diagnosis-related groups with compulsory information for each hospital stay including socio-demographic characteristics of patient, diagnoses using the International Classification of Diseases, tenth revision (ICD-10), and procedures using the French classification of medical acts (Classification Commune des Actes Médicaux, <https://www.ameli.fr/accueil-de-la-ccam/index.php>). The reliability and validity of PMSI data have already been assessed. This data source was previously used in similar studies [20, 22–24].

Population

The study population included all patients with acute leukemia aged 18 years and older who died during a hospital stay between January 1, 2017, and December 31, 2018. The patients were identified using the algorithm developed by the French National Cancer Institute (INCa, <https://aide.groupepsih.com/docs/pmsi-pilot-cancero/principes-generaux/algorithmme-inca/>, last access 2021, October, 31th), which was specifically designed to identify cancer patients with routinely collected data (codes of diagnosis, codes of medical acts) (Additional file 1). The selection of patients was based on the ICD-10 leukemia-related codes (Additional file 1). The population included only patients in a palliative care situation defined by at least: 1. one code Z515 during the 3 months preceding death (Z515 can be used by the coders if the patient has a palliative care consultant during the hospitalization but also if the healthcare team considers the patient in a palliative phase); and-or 2. being in an inpatient palliative care support bed during the 3 months preceding death (in France, a palliative bed is a bed in a palliative care unit or a bed in another care unit dedicated to a palliative patient). In France, the palliative teams are only assisting with symptom management (not addressing the intensity of care). The patients with a combination of myeloid and lymphoid leukemia were excluded due to: 1) worse prognosis, 2) heterogeneous therapeutic strategies.

Endpoints

Intensity end-of-life care was assessed using two endpoints: high intensive end-of-life (HI-EOL) care and Most Invasive End-of-Life (MI-EOL) care. HI-EOL care and MI-EOL care definitions were proposed by Earle et al. [13, 25, 26] and jointly endorsed by the National Quality Forum and the American Society of Clinical Oncology.

HI-EOL care is defined by the occurrence of at least one of the following indicators: 1. at least one intensive care unit (ICU) admission in the last 30 days of life; 2. more than one emergency department admission in the

last 30 days of life; 3. more than one acute care hospitalization in the last 30 days of life; or 4. at least one intravenous chemotherapy treatment in the last 14 days of life.

MI-EOL care is defined by the occurrence of at least one of the following indicators in the last 30 days of life: 1. orotracheal intubation; 2. mechanical ventilation; 3. artificial feeding (enteral or parenteral); 4. cardiopulmonary resuscitation; 5. gastrostomy; or 6. Hemodialysis.

Factors associated with end-of-life care intensity

The factors are detailed in the Additional file 1.

Statistical analysis

The rates of patients receiving HI-EOL care, MI-EOL care, and each constitutive element are provided. To assess the associations between the two endpoints (HI-EOL and MI-EOL, used as separate dependent variables) and sociodemographic, clinical, and hospital data, univariate and multivariate analyses were performed. Variables selected for the multivariate models were: age classes, sex, year of death, social living area, type of leukemia, allogeneic stem cell transplantation, comorbidities, type of hospital, time in a palliative care structure, time between the patients' home and the hospital, and length of stay. A generalized estimating equation (GEE) was performed to estimate the parameters while taking into account the intrahospital cluster effect (PROC GLIMMIX procedure model, SAS V9.4). The results are presented as adjusted odds ratios (AORs) and their 95% confidence intervals (95% CIs). Statistical significance was defined as $p < 0.05$. Statistical analysis was performed with SAS 9.4 (SAS Institute).

Results

Sample

A total of 3658 patients who died at the hospital between January 1, 2017 and December 31, 2018 were included in the study. We excluded 376 patients with unspecified acute leukemia, 116 patients with a combination of myeloid and lymphoid leukemia, and 3252 patients not in a palliative care situation. A flow diagram detailing the selection of cases is shown in Fig. 1. Twenty-nine percent of the patients were aged under 70 years at the time of death and they were predominantly men (56%). A majority (55%) of the population was living in a socially disadvantaged area. The patients predominantly presented with acute myeloid leukemia (94%) and 7% of them had undergone allogeneic stem cell transplantation. Almost 15% of the patients died in an intensive care structure, 25% of them were hospitalized for more than 1 month, and 30% spent time more than 1 month in a palliative care structure before death. All details are shown in Table 1.

Intensity of end-of-life care


In the last 30 days of life, 63 and 13% of the patients received HI-EOL care and MI-EOL care, respectively. For 20% of the patients, care was managed in an intensive care unit, and 11% of them were mechanically ventilated. All the items constituting HI-EOL/MI-EOL care are presented in Fig. 2.

Factors associated with HI-EOL care and MI-EOL care

Age, sex, year of death, social living area, type of leukemia, allogeneic stem cell transplantation, comorbidities, type of hospital, time in a palliative care structure, time between the patients' home and hospital, and length of stay were entered in the multivariate models to assess factors associated with HI-EOL and MI-EOL. HI-EOL care was more often received by younger individuals. The patients with a higher number of comorbidities, hospitalization in specialized cancer centers, a lower time in a palliative care structure, and a longer length of stay were more often associated with HI-EOL care. MI-EOL care was also more often used for younger patients, men, and patients living in a disadvantaged area. The patients with acute myeloid leukemia, a lower time in a palliative care structure, and a longer length of stay were more often associated with MI-EOL care. The multivariate analysis results are detailed in Table 2.

Discussion

The first important finding of this study was the high proportion of high intensive end-of-life care (63%) during the last days before death in French patients presenting with acute leukemia who died in the hospital. The proportion of most intensive end-of-life care according to the Earle definition was, in contrast, lower (13%). These findings were close to those of studies conducted in similar populations. In the study conducted by Beaussant et al. [19], based on the same French national hospital register but focusing on an older period (2010–2013) and on a larger panel of hematological malignancies (including acute leukemia), some results are relatively consistent with our findings: 26% of patients received a chemotherapy in the last month versus 20% in our results, artificial feeding was used for 7% versus 3% in our cohort, dialysis was used in 5% versus 1% in our study, cardiopulmonary resuscitation was used for less than 2% versus 1.7% in our study. Likewise, in recent studies [18, 20] exploring younger populations (children, adolescents, and young adults with cancer), the authors observed high rates of patients who experienced intensive end-of-life care with significantly higher risk for the group with hematological



malignancies. Higher rates were reported in other studies, but they included smaller samples, older patients, and data older than 10 years [16, 21].

These high rates of aggressive end-of-life care may be partially explained. First, in comparison with patients who presented with other malignancies, patients with hematological malignancies (especially patients with acute leukemia) present with a high frequency of hematological complications (bleeding, thromboembolic events, and severe anemia). These complications require

emergency treatments, such as transfusions, intravenous antibiotic infusions, and other acute interventions, such that the hospital is often the more comfortable place for treatment administration and monitoring. Second, hematologic oncologists present specificities in their attitudes and beliefs toward end-of-life care. Compared with solid tumor specialists, they are more likely to recommend cancer therapy to patients with poor performance status and short expected survival, and they are less comfortable with end-of-life care [15]. Even if hematologic

Table 1 Socio-demographic, clinical, and hospital characteristics of the 3658 patients

Socio-demographic data	N (%)
Age at death (years)	
< 60	417 (11.4)
[60–70]	623 (17.0)
[70–80]	1150 (31.4)
≥ 80	1468 (40.1)
Sex	
Male	2037 (55.7)
Female	1621 (44.3)
Year of death	
2017	1813 (49.6)
2018	1845 (50.4)
Social area living	
Socially advantaged	1608 (44.0)
Socially disadvantaged	2001 (54.7)
Missing data	49 (1.3)
Clinical Data	N (%)
Type of leukemia	
Acute myeloid leukemia	3426 (93.7)
Acute promyelocytic leukemia	20 (0.6)
Acute myelomonocytic leukemia	170 (4.7)
AML with 11q23	19 (0.5)
AML with dysplasia of several cell lines	161 (4.4)
Acute monoblastic/monocytic leukemia	123 (3.4)
Acute pan myelosis with myelofibrosis	72 (2.0)
Megakaryocyte leukemia	22 (0.6)
Acute erythroid leukemia	31 (0.9)
Acute lymphoid leukemia	231 (6.3)
Months between diagnosis and death	
≤ 3	703 (19.2)
[3–12]	806 (22.0)
[12–36]	1084 (29.6)
> 36	1065 (29.1)
Allogeneic stem cell transplantation	
No	3394 (92.8)
Yes	264 (7.2)
Charlson score (co-morbidities) ^a	
0	1459 (39.9)
1–2	1411 (38.6)
≥ 3	788 (21.5)
Last hospitalization stay	N (%)
Type of hospital ^c	
Non-specialized hospital	2245 (61.4)
Specialized hospital	1413 (38.6)
Death in an intensive care structure	495 (13.5)
Palliative care structure in the last 3 days of life ^b	745 (20.4)
Time in a palliative care structure before death	
≤ 1 month	2545 (69.6)
> 1 month	1113 (30.4)

Table 1 (continued)

Travel time from patients' home (minutes)	
≤ 10	1047 (28.6)
[10–30]	1071 (29.3)
[30–60]	652 (17.8)
> 60	945 (21.8)
Length of stay (days)	
≤ 15	1382 (37.8)
[15–30]	1361 (37.2)
> 30	929 (25.0)


^a Charlson modified score (excluding malignancies/metastasis)

^b Intensive care structure includes intensive care unit, resuscitation unit, emergency unit

^c Specialized centers include cancer units of an university hospital and units of a cancer hospital, non-specialized centers include all the other cases

oncologists report the ability to identify key points in the disease trajectory signifying that end of life is near, they report the absence of a clear definition of the end of life for hematological cancers [15]. Hematologic oncologists report feeling a sense of failure when they are not able to alter the course of disease [15] and have more difficulties sharing prognosis and transition in care with their patients than other oncologists [17]. End-of-life discussions in hematologic oncology often occur too late [17]. It has been shown that focused communication skills training can improve physicians' abilities to empathically help patients achieve their goals while balancing benefits and burdens [27]. Third, two kinds of aggressive care [17] should be distinguished. Some aspects of intensive care may be considered physician-initiated events (such as hospital admission, chemotherapy administration, intubation) that are influenced by advance care discussions between physicians and patients. Conversely, the decision to present to an emergency unit largely depends on patients and their families themselves and is less likely amenable to physician-driven process intervention. This distinction deserves to be emphasized in future perspectives on improving end-of-life care quality. While some barriers can be reduced with physicians' interventions, others need discussions with the patients. This highlights the importance of engagement in advance care planning processes [28, 29] that are still insufficient for cancer patients [30].

The second interesting finding relies on the fact that acute lymphoid leukemia patients did not receive more intensive end-of-life care than patients with acute myeloid leukemia, contrary to what other reports found [31]. This result may be partially due to the selection of our sample, that included only patients in a palliative situation.



A third finding drew our attention. An earlier introduction of a palliative care management was a real benefit to protect against aggressive end of life care, as already described in previous studies [32, 33] including randomized trials [9, 34]. Even if having care managed by a palliative structure did not totally protect against invasive/aggressive care during the last days of life [35], earlier palliative intervention had a positive impact on treatment aggressiveness [34]. Nevertheless, as this approach was less often discussed, it is urgent to convince a greater number of centers to plan an earlier transition from curative interventions to palliative care. Qualitative studies may help to identify barriers [36] and provide targeted actions.

Other less expected associations with intensive end-of-life care were found. We hypothesized that the presence of comorbidities, as a reflection of worse health status, would be associated with less intensive end-of-life care, but we found the opposite result. Likewise, compared with nonspecialized cancer centers, we hypothesized that specialized cancer centers, by incorporating multidisciplinary teams, would be less associated with high intensity care [20]. These counterintuitive results may reflect the difficulty of transitioning from curative to palliative objectives. It is now necessary to combine the most

advanced technology and therapeutics (such as targeted therapies or allogeneic stem cell transplantation) with consideration of the best end-of-life care quality. Interestingly, the oldest patients were those who benefited least from intensive end-of-life care: this finding was also found in previous reports [20].

Strengths and limitations

The main strengths are as follows: (1) The study is the first study focusing on acute leukemia in a palliative care situation; and (2) The study includes a large population enrolled in recent years (2017–2018). Some limitations should be discussed: (1) Only patients who died in hospitals were studied, and future studies should explore the phenomenon in other conditions of death, such as patients whose care was managed in rehabilitation centers and at home. This would provide a more valid picture of patients with acute leukemia at the end of life, providing factors associated with the risk of dying in hospitals in France. This may also help improve coordination within the health care delivery system, including specific and general hospitals and ambulatory care. (2) The retrospective design prevented us from truly exploring the relations between the expected prognosis of the patient and the decision

Table 2 Factors associated with High Intensive End-of-Life (HI-EOL) and Most Invasive End-of-Life (MI-EOL) care (Multivariate Analyses)

	HI-EOL			MI-EOL		
	N = 2316 (63,31%)			N = 471 (12,88%)		
	N (%)	AOR (CI 95%)	p-value	N (%)	AOR (CI 95%)	p-value
Age at death (years)						
< 60 (ref)	315 (75.5)	–		94 (22.5)	–	
[60;70]	459 (73.7)	0.968 (0.708–1.325)	0.841	124 (19.9)	0.959 (0.686–1.341)	0.807
[70;80]	734 (63.8)	0.688 (0.512–0.926)	0.014	128 (11.13)	0.558 (0.394–0.791)	0.001
> =80	808 (55.0)	0.536 (0.400–0.720)	< 10⁻³	125 (8.51)	0.445 (0.311–0.635)	< 10⁻³
Sex						
Man (ref)	1324 (65.0)	–		278 (13.7)	–	
Woman	992 (62.1)	0.891 (0.770–1.033)	0.125	193 (11.9)	0.940 (0.761–1.161)	0.567
Year of Death						
2017 (ref)	1126 (62.1)	–		220 (12.1)	–	
2018	1190 (64.5)	1.072 (0.928–1.239)	0.346	251 (13.6)	1.104 (0.899–1.356)	0.344
Social area living						
Socially advantaged (ref)	1028 (63.9)	–		204 (12.7)	–	
Socially disadvantaged	1245 (62.2)	0.944 (0.811–1.100)	0.464	261 (13.0)	1.077 (0.866–1.340)	0.506
Type of leukemia						
Acute myeloid leukemia (ref)	2154 (62.8)	–		426 (12.4)	–	
Acute lymphoid leukemia	162 (69.8)	1.063 (0.773–1.460)	0.708	45 (19.4)	1.216 (0.840–1.760)	0.300
Allo-SCT						
No (ref)	2109 (62.1)	–		400 (11.8)	–	
Yes	207 (78.4)	1.186 (0.832–1.692)	0.345	71 (26.9)	1.335 (0.934–1.906)	0.113
Charlson score (co-morbidities) ^a						
0 (ref)	870 (59.66)	–		149 (10.2)	–	
1–2	939 (66.6)	1.300 (1.104–1.532)	< 10⁻³	190 (13.5)	1.317 (1.033–1.679)	0.003
≥ 3	507 (64.3)	1.142 (0.939–1.89)	0.184	132 (16.8)	1.720 (1.312–2.253)	< 10⁻³
Type of hospital ^b						
Non-specialized hospital (ref)	1328 (59.2)	–		217 (9.7)	–	
Specialized hospital	988 (69.9)	1.357 (1.157–1.592)	< 10⁻³	254 (18.0)	1.634 (1.312–2.034)	< 10⁻³
Time in a palliative care structure						
≤ 1 month (ref)	1611 (63.3)	–		336 (13.2)	–	
> 1 month	705 (63.3)	0.577 (0.481–0.690)	< 10⁻³	135 (12.1)	0.659 (0.509–0.853)	0.002
Time from patients' home (minutes)						
≤ 10 (ref)	617 (58.9)	–		108 (10.3)	–	
[10–30]	684 (63.9)	1.224 (1.017–1.474)	0.032	131 (12.2)	1.164 (0.79–1.542)	0.289
[30–60]	404 (62.0)	1.114 (0.897–1.382)	0.330	81 (12.4)	1.161 (0.840–1.604)	0.366
> 60	537 (67.5)	1.205 (0.977–1.486)	0.081	138 (17.3)	1.335 (0.934–1.906)	0.113
Length of stay (days)						
< 7 (ref)	250 (47.1)	–		46 (10.4)	–	
[7–15]	514 (60.3)	2.114 (1.650–2.709)	< 10⁻³	81 (10.0)	0.910 (0.608–1.361)	0.645
[15–30]	936 (68.8)	4.053 (3.212–5.114)	< 10⁻³	197 (13.2)	1.159 (0.807–1.663)	0.425
> 30	704 (76.9)	7.104 (5.389–9.365)	< 10⁻³	147 (16.1)	1.474 (0.994–2.186)	0.054

HI-EOL: High Intensive End-of-Life (at least one of the following indicators: 1. at least one intensive care unit (ICU) admission in the last 30 days of life; 2. more than one emergency department admission in the last 30 days of life; 3. more than one acute care hospitalization in the last 30 days of life; or 4. at least one intravenous chemotherapy treatment in the last 14 days of life)

MI-EOL: Most Invasive End-of-Life (at least one of the following indicators in the last 30 days of life: 1. orotracheal intubation; 2. mechanical ventilation; 3. artificial feeding (enteral or parenteral); 4. cardiopulmonary resuscitation; 5. gastrostomy; or 6. hemodialysis)

Allo-SCT: Allogeneic stem cell transplantation

AOR (95% CI): adjusted odd ratio (95% confidence interval)

^a Charlson modified score (excluding malignancies/metastasis)

^b Specialized centers include cancer units of an university hospital and units of a cancer hospital, non-specialized centers include all the other cases

ref: reference modality for the AOR

Bold values: p-value < 0.05

regarding intensive care treatments, such as chemotherapy administration, intensive care unit admission, and mechanical ventilation implementation. Physicians have been found to be overoptimistic regarding the prognosis of terminally ill patients [37]. (3) The accuracy of the findings, due to the source of the data (an administrative registry), depends on the coding rules and the skills of the coders [38]. These databases were originally designed for the optimization of funding allocation for the French health facilities, but the coding procedures have moved progressively towards those of a medical record database.

Conclusion

A majority of French adults, young adults, and adolescents with acute leukemia in a palliative care situation who died at the hospital, experienced high-intensity end-of-life care. Identification of factors associated with intensity end-of-life care, such as the access to palliative care and specialized cancer center care management, may help to improve end-of-life care quality.

Abbreviations

AORs: Adjusted odds ratios; EOL: End-of-life; HI-EOL care: High intensive end-of-life care; ICD-10: Classification of Diseases, tenth revision; INCa: French National Cancer Institute; MI-EOL care: Most invasive end-of-life care; PMSI: Programme de Médicalisation des Systèmes d'Information.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12904-022-00937-0>.

Additional file 1. Details of materials and methods.

Acknowledgments

We thank Françoise Volot (Department of Medical Information, APHM, Marseille, France) for her expertise of the coding procedures.

Authors' contributions

SS: conception and design, coordination, interpretation of data, drafting and writing of manuscript; VP: conception and design, analysis of data; MD: conception and design, analysis of data, interpretation of data; VO: conception and design, analysis of data; GF: methodology guidance, interpretation of data; RC: interpretation of data; LB: conception and design, coordination, methodology guidance, interpretation of data, drafting and writing of manuscript; KB: conception and design, interpretation of data, drafting and writing of manuscript; All the authors: revision and approval of final version of the manuscript.

Funding

No funding.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available: they were used under license for the current study (French national hospital database, the Programme de Médicalisation des Systèmes d'Information) but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All methods were carried out in accordance with relevant French and European guidelines and regulations. Since 16 July 2018, the French National Data Protection Committee (CNIL) published revised and new reference methods <<http://email.practicallaw.com/c/11mbxSsvUpleFV1hFaWpN815Pkl>> (MRs) regarding data processing in health research to adapt the existing framework to the EU General Data Protection Regulation (GDPR) and the national health data system (SNDS). MR-005 declaration is necessary to access to the programme for the medicalisation of information systems (PMSI) as in our study. This study was approved by the French National Data Protection Committee (CNIL): authorization number MRO05 N° 155160102192019. Informed consent was not obtained because the PMSI database is anonymous.

Consent for publication

Not applicable.

Competing interests

The authors have declared no conflicts of interest.

Author details

¹Department of Palliative Care, Oncology, APHM, Marseille, France. ²Department of Medical Information, APHM, Marseille, France. ³CEReSS - Health Service Research and Quality of Life Center, Aix-Marseille University, EA 3279, 27 bd Jean Moulin, cedex 05, F-13385 Marseille, France. ⁴Hematology and Cellular Therapy Department, APHM, Marseille, France. ⁵Department of Epidemiology and Health Economics, APHM, Marseille, France.

Received: 25 May 2021 Accepted: 25 March 2022

Published online: 02 April 2022

References

- Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. *Lancet*. 2018;392(10147):593–606.
- Torpy JM, Lynn C, Glass RM. JAMA patient page. Acute lymphoblastic leukemia. *JAMA*. 2009;301(4):452.
- Epstein AS, Goldberg GR, Meier DE. Palliative care and hematologic oncology: the promise of collaboration. *Blood Rev*. 2012;26(6):233–9.
- Fadul NA, El Osta B, Dalal S, Poulter VA, Bruera E. Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. *J Palliat Med*. 2008;11(3):422–7.
- Manitta VJ, Philip JA, Cole-Sinclair MF. Palliative care and the hemato-oncological patient: can we live together? A review of the literature. *J Palliat Med*. 2010;13(8):1021–5.
- Zimmermann C, Yuen D, Mischitelle A, Minden MD, Brandwein JM, Schimmer A, et al. Symptom burden and supportive care in patients with acute leukemia. *Leuk Res*. 2013;37(7):731–6.
- Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. *J Clin Oncol*. 2007;25(14):1908–15.
- De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. *Blood Cancer J*. 2016;6(7):e441.
- Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010;363(8):733–42.
- Maddocks I, Bentley L, Sheedy J. Quality of life issues in patients dying from haematological diseases. *Ann Acad Med Singap*. 1994;23(2):244–8.
- Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. *Palliat Med*. 2011;25(6):630–41.
- Alt-Epping B, Wulf G, Nauck F. Palliative care for patients with hematological malignancies—a case series. *Ann Hematol*. 2011;90(5):613–5.
- Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? *J Clin Oncol*. 2008;26(23):3860–6.

14. Howell DA, Roman E, Cox H, Smith AG, Patmore R, Garry AC, et al. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. *BMC Palliat Care*. 2010;9:9.
15. Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, et al. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. *Ann Oncol*. 2015;26(7):1440–6.
16. Hui D, Didwaniya N, Vidal M, Shin SH, Chisholm G, Roquemore J, et al. Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. *Cancer*. 2014;120(10):1572–8.
17. Odejide OO, Cronin AM, Condrion NB, Fletcher SA, Earle CC, Tulsy JA, et al. Barriers to quality end-of-life Care for Patients with Blood Cancers. *J Clin Oncol*. 2016;34(26):3126–32.
18. Johnston EE, Alvarez E, Saynina O, Sanders L, Bhatia S, Chamberlain LJ. End-of-life intensity for adolescents and young adults with Cancer: a Californian population-based study that shows disparities. *J Oncol Pract*. 2017;13(9):e770–81.
19. Beaussant Y, Daguindau E, Chauchet A, Rochigneux P, Tournigand C, Aubry R, et al. Hospital end-of-life care in haematological malignancies. *BMJ Support Palliat Care*. 2018;8(3):314–24.
20. Revon-Riviere G, Pauly V, Baumstarck K, Bernard C, Andre N, Gentet JC, et al. High-intensity end-of-life care among children, adolescents, and young adults with cancer who die in the hospital: a population-based study from the French national hospital database. *Cancer*. 2019;125(13):2300–8.
21. El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, et al. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. *Cancer*. 2015;121(16):2840–8.
22. Boudemaghe T, Belhadji I. Data resource profile: the French National Uniform Hospital Discharge Data set Database (PMSI). *Int J Epidemiol*. 2017;46(2):392–392d.
23. Fond G, Pauly V, Duba A, Salas S, Viprey M, Baumstarck K, et al. End of life breast cancer care in women with severe mental illnesses. *Sci Rep*. 2021;11(1):10167.
24. Viprey M, Pauly V, Salas S, Baumstarck K, Orleans V, Llorca PM, et al. Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study. *Eur Arch Psychiatry Clin Neurosci*. 2021;271(8):1571–8.
25. Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. *J Clin Oncol*. 2003;21(6):1133–8.
26. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. *J Clin Oncol*. 2004;22(2):315–21.
27. Dharmarajan KV, Wei R, Vapiwala N. Primary palliative care education in specialty oncology training: more work is needed. *JAMA Oncol*. 2016;2(7):858–9.
28. Kelly EP, Henderson B, Hyer M, Pawlik TM. Intrapersonal factors impact advance care planning among Cancer patients. *Am J Hosp Palliat Care*. 2021;138(8):907–913.
29. Marchi L, Santos Neto MFD, Moraes JP, Paiva CE, Paiva BSR. Influence of advance directives on reducing aggressive measures during end-of-life cancer care: a systematic review. *Palliat Support Care*. 2021;19(3):348–354.
30. Boulanger A, Chabal T, Fichaux M, Destandau M, La Piana JM, Auquier P, et al. Opinions about the new law on end-of-life issues in a sample of french patients receiving palliative care. *BMC Palliat Care*. 2017;16(1):7.
31. Johnston EE, Muffly L, Alvarez E, Saynina O, Sanders LM, Bhatia S, et al. End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: a population-level analysis. *J Clin Oncol*. 2018;36(30):3023–30.
32. Pritchard S, Cuvelier G, Harlos M, Barr R. Palliative care in adolescents and young adults with cancer. *Cancer*. 2011;117(10 Suppl):2323–8.
33. Colombet I, Bouleuc C, Piolot A, Vilfaillot A, Jaulmes H, Voisin-Saltiel S, et al. Group Es: multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation. *BMC Palliat Care*. 2019;18(1):35.
34. Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codeca C, et al. Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. *Eur J Cancer*. 2016;69:110–8.
35. Cheng BH, Sham MM, Chan KY, Li CW, Au HY. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. *Am J Hosp Palliat Care*. 2015;32(2):221–5.
36. LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. *Blood*. 2018;132(7):717–26.
37. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. *BMJ*. 2003;327(7408):195–8.
38. Anthun KS, Bjorngaard JH, Magnussen J. Economic incentives and diagnostic coding in a public health care system. *Int J Health Econ Manag*. 2017;17(1):83–101.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

